Innovent Biologics stock
1801.HKHKSEInnovent Biologics, Inc., HealthcareISIN KYG4818G1010
61Score 61 out of 100, Neutral
Price and trend
64 / 100
Price history
−0.1% in one yearThe chart shows daily closes over 8 years, adjusted for stock splits and without dividends. Click into the chart to set a price alert at that price.
Below the 200-day line: the price is 0.8% below it.
Since August 2026 the 50-day line has been above the 200-day line; the trend has turned up.
Normal: the price is neither overheated nor sold off (RSI 59).
The price is 21% below its 52-week high. Largest decline in 8 years: 82% (January 2021 to May 2022).
Chart figures for advanced users
- SMA 50$11.76
- Average price of the last 50 trading days, shows the short-term trend.
- SMA 200$11.19
- Average price of the last 200 trading days, shows the long-term trend.
- RSI (14)59
- Relative strength over the last 14 days on a scale from 0 to 100. Above 70 the price counts as overheated, below 30 as sharply fallen.
- MACDabove the signal line
- Compares a fast and a slow price average. Above its signal line momentum is rising, below it momentum is fading.
- Support$9.30
- The lowest closing price of the last twelve months.
- Resistance$14.00
- The highest closing price of the last twelve months.
Snapshot
Computed from the data by fixed rules, no AI
- Innovent Biologics, Inc. belongs to the Biotechnology industry (China) and, with a market value of $19.36B, is number 19 of 296 companies in its industry on MEQIRI.
- MEQIRI Score 61 out of 100 (Neutral): rank 253 of 714 in Healthcare, median 53.
- The P/E is 109.8 (Biotechnology median 46.6, own median of recent years 142.7).
Show more
- Our model puts fair value at $13.75, with the price 20% below it.
In plain words
The numbers on this page in plain words, written by an AI
Strengths
- Earnings turn into cashFree cash flow above 500% of earnings over the last 12 months.Fundamentals 60
- Analysts expect strong earnings growthUp 43.5% a year through 2028 (estimates from 25 analysts).Growth 70
- More cash than debtCash $3B, financial debt $348.21M.Stability 75
Weaknesses
- DilutionShare count up 28% since 2020.Capital allocation 54
- Volatile share priceVolatility 46% a year over the last 12 months.
Its standout strengths are stability and growth, while momentum and valuation hold the score back.
Daily figure as of 12 Nov 2026
How the score is calculatedScore overview
Score since yesterday from 62 to 61.
The fundamentals are in the middle range.
Score history
The full history of up to 20 years comes with MEQIRI Pro.
See plansCrash risk not measured
How well MEQIRI warnsFor stocks from Japan, China, Hong Kong, Taiwan, Korea, Canada, India and Brazil we only show crash risk once a separate backtest shows that it warns as well there as in the US and Europe.
Valuation
Valuation signal
Modestly undervaluedClosing price of 11 Nov 2026, used by the daily score.
In our model the price counts as cheap below $9.82 and expensive above $22.92 (uncertainty high, based on the price swings of the past year).
The two parts of the fair value come to $22.79 (cash-flow model) and $4.71 (industry comparison), and the gap between them shows how uncertain the estimate is.
Calculated with a cost of equity of 8.6%. At 9.6% the fair value would be $11.87, at 7.6% it would be $16.37.
Valuation metrics
Half from the cash-flow model, half from earnings times the industry P/E (46.6).
Calculate with your own assumptionsCompany performance
This shows several years of history with an automatic assessment.
Revenue
In the twelve months to 30 Jun 2026, revenue rose 36.5% on the twelve months before. Revenue has grown strongly since 2016, at around 95% per year.
Margins
- Gross margin
- Operating margin
- Net margin
In fiscal 2025: gross 77%, operating 6%, net 6%.
Debt & balance sheet
latest quarterThe balance sheet is solid, with low debt and comfortable interest coverage.
Earnings
- Next earnings
- 31 Mar 2027in 139 days
- Last reported
- 25 Aug 2026EPS reported 0.81 (expected 0.54)above expectations
Analyst estimates
Earnings estimates have barely changed since 27 Oct 2026.
- Earnings per share
- 1.4+0.4%
- Revenue
- $2.85B+0.2%
- Earnings per share
- 2.18+0.5%
- Revenue
- $3.58B+0.2%
MEQIRI has stored the estimates since 27 Oct 2026. Until 30 days are available, the card shows the change since that day. Mean estimate according to Financial Modeling Prep. No price target and no recommendation.
What happened at Innovent Biologics
The key events of the last six months from our own data. A click takes you to the matching card.
Sector comparison
714 rated companies in Healthcare
- This company
- 61
- Sector median
- 53
Categories against the sector median
The median is the middle value: half of the companies in the sector lie above it, half below. Categories with too few comparable companies are left out.
Competitors in Biotechnology
The next larger and next smaller companies by market value
- United TherapeuticsUTHR $25.37B81
- IncyteINCY $24.92B70
- BioNTechBNTX $21.73B37
- Alnylam PharmaceuticalsALNY $21.41B57
- ExelixisEXEL $17.77B90
- Neurocrine BiosciencesNBIX $17.65B77
- Ascendis PharmaASND $17.06B69
- Jazz PharmaceuticalsJAZZ $15.93B66
ETFs that hold Innovent Biologics
Held by 57 ETFs on Xetra. Shown per index: the ETF with the largest weight.
| ETF | Weight | Cost | Fund size |
|---|---|---|---|
| UBS Solactive China Technology UCITS ETF USD accUIC2 | 2.80% | 0.47% | €255.87M |
| Amundi MSCI China ESG Selection Extra UCITS ETF AccLCHI | 1.24% | 0.65% | €473.19M |
| iShares Dow Jones China Offshore 50 UCITS ETF (DE)EXXU | 1.24% | 0.62% | €40.6M |
Show 5 more
| UBS MSCI China Universal UCITS ETF USD disUETC | 1.09% | 0.30% | €134.65M |
| iShares BIC 50 UCITS ETFIQQ9 | 0.95% | 0.74% | €99.3M |
| Deka MSCI China ex A Shares UCITS ETFEL46 | 0.89% | 0.65% | €74.12M |
| iShares MSCI EM Consumer Growth UCITS ETFCEMG | 0.73% | 0.60% | €31.52M |
| Xtrackers MSCI China UCITS ETF 1CXCS6 | 0.67% | 0.65% | €1.51B |
Holdings as reported by the funds via FMP, excluding swap ETFs (their holdings are only collateral).
Data status and sources
- Score
- Daily value of 12 Nov 2026, recalculated nightly
- Price
- Closing price of 12 Nov 2026
- Latest annual report
- Fiscal year 2025, period end 31 Dec 2025
- Currency
- Amounts in US dollars, converted at the ECB reference rate of 11 Nov 2026 ($1 = HK$7.8456, $1 = CN¥6.6707)
- Source
- Financial statements, ratios and prices from Financial Modeling Prep (FMP), based on the company's reports. MEQIRI calculates the score and fair value from them.
Mandatory disclosures for this rating
- ; time horizon around 12 months
- Rated Neutral, published since 7 Nov 2026 (in the score history since 19 Jun 2026)
- Valuation signal Fairly valued since 7 Nov 2026
- End-of-day prices, metrics cached for up to 24 hours
- Score and fair value are estimates from a disclosed model. They are not facts and not a price target.
- Produced by SSM Ventures UG (haftungsbeschränkt), responsible person Sven Brostmeyer, Managing Director, automatically according to the disclosed model.
- Not investment advice. Losses up to and including a total loss are possible. Personal circumstances are not considered.